Deutsche Bank Aktiengesellschaft Upgrades Haleon (LON:HLN) to Hold

Haleon (LON:HLN) was upgraded by investment analysts at Deutsche Bank Aktiengesellschaft to a “hold” rating in a research report issued to clients and investors on Friday, Digital Look reports. The brokerage currently has a GBX 310 target price on the stock, down from their prior target price of GBX 320. Deutsche Bank Aktiengesellschaft‘s target price points to a potential downside of 4.26% from the stock’s previous close.

Several other equities analysts have also weighed in on the company. Jefferies Financial Group restated a “buy” rating and set a GBX 400 target price on shares of Haleon in a report on Friday. Royal Bank Of Canada upped their price target on Haleon from GBX 370 to GBX 390 and gave the stock a “sector perform” rating in a research note on Tuesday, August 11th. Finally, Berenberg Bank increased their price objective on Haleon from GBX 512 to GBX 514 and gave the company a “buy” rating in a report on Wednesday, August 5th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of GBX 385.80.

Haleon Stock Up 1.9%

HLN stock traded up GBX 6.10 during trading hours on Friday, hitting GBX 323.80. The company’s stock had a trading volume of 1,049,375,500 shares, compared to its average volume of 32,993,621. The stock has a 50 day moving average price of GBX 353.77 and a two-hundred day moving average price of GBX 360.62. Haleon has a 12 month low of GBX 310.50 and a 12 month high of GBX 433.60. The company has a market capitalization of £28.48 billion, a PE ratio of 17.89, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. The company has a quick ratio of 0.93, a current ratio of 0.69 and a debt-to-equity ratio of 50.38.

Haleon (LON:HLN) last released its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 earnings per share (EPS) for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. On average, equities research analysts expect that Haleon will post 19.50 earnings per share for the current year.

Haleon declared that its Board of Directors has approved a share repurchase plan on Thursday, October 29th that permits the company to repurchase £500 million in shares. This repurchase authorization permits the company to purchase up to 1.8% of its shares through open market purchases. Stock repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Key Haleon News

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon approved a £500 million share repurchase programme, allowing it to buy back up to 1.8% of outstanding shares through open-market purchases. The authorization may support earnings per share and signals management’s view that the stock is undervalued. Haleon Q3 Revenue Rises; Trims Annual Revenue Growth Outlook; Launches £500 Mln Share Buyback
• Neutral Sentiment: Management maintained its profit outlook while launching the repurchase plan, which could limit the earnings impact of softer sales. However, the buyback is primarily a capital-return measure and does not resolve the company’s near-term growth challenges. Haleon Launches £500m Share Buyback to Cut Capital and Support Employee Plans
• Negative Sentiment: Third-quarter organic revenue growth was 2.6%, below expectations, prompting Haleon to cut its 2026 organic growth forecast to about 2.5% from the previous 3%–5% range. The downgrade is the main reason the stock declined sharply. Haleon drops after Q3 sales miss and lower 2026 growth outlook
• Negative Sentiment: Haleon cited weaker cough, cold and flu consumption in North America, disruption to OTC-registered Centrum products in China, and an expected fourth-quarter revenue hit from an accelerated go-to-market change in Brazil. These issues raise concerns about uneven demand and execution across key markets. Sensodyne maker Haleon cuts revenue growth forecast on weak flu season, China disruption

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.